ImmuPharma plc (LON:IMM – Get Free Report) shares fell 19.5% during mid-day trading on Thursday . The stock traded as low as GBX 3.21 and last traded at GBX 3.21. 1,367,494 shares were traded during trading, a decline of 44% from the average session volume of 2,443,213 shares. The stock had previously closed at GBX 3.98.
ImmuPharma Price Performance
The stock has a market capitalization of £20.00 million, a price-to-earnings ratio of -8.66 and a beta of 3.01. The stock has a 50-day moving average of GBX 3.85 and a 200 day moving average of GBX 4.33.
ImmuPharma (LON:IMM – Get Free Report) last issued its earnings results on Tuesday, September 15th. The company reported GBX (0.84) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 633.14%. Sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
